Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442801 | 1.00 | HTT (0.50) | HTTPKMSMN1; SMN2CTSSCAPN1 | |
| SCHEMBL5839241 | 0.84 | SMN1; SMN2 (0.64) | HTTPKMSMN1; SMN2CTSSNPSR1 | |
| SCHEMBL6445944 | 0.84 | SMN1; SMN2 (0.64) | HTTPKMSMN1; SMN2CTSSNPSR1 | |
| SCHEMBL6448464 | 0.77 | SMN1; SMN2 (0.51) | HTTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL6448460 | 0.77 | SMN1; SMN2 (0.51) | HTTSMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL6857049 | 0.75 | HTT (0.42) | HTTPKMSMN1; SMN2CTSSCAPN1 | |
| Valine SCHEMBL6447749 | 0.75 | HTT (0.50) | HTTPKMSMN1; SMN2CTSSNPC1 | |
| SCHEMBL6442995 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL6442998 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL6444661 | 0.73 | HTT (0.63) | HTTPKMSMN1; SMN2CTSSNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | HTT 55/4885PKM 2587/4885SMN1; SMN2 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.